Bristol Myers Squibb

News

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

News

Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.

News

Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.

News

BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.

News

MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.

News

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.